Frequently Asked Questions

---

There are only 3 qualifications 

Must be an Ohio resident 

BMI over 30 or greater and no weight-related complications

BMI over 27 with weight-related complications such as hypertension or dyslipidemia 

Semaglutide is a member of a class of drugs that have been used for diabetes management for over a decade - GLP1-RAs (glucagon-like peptide 1 receptor agonists). 

In terms of weight loss, Semaglutide increases the sensation of “fullness” and decreases appetite and cravings by delaying gastric emptying. This results in a decreased caloric intake and shedding of pounds.

In terms of science, Semaglutide is a GLP-1 hormone that acts on your brain to regulate hunger and food intake. It works by increasing insulin release, lowering the amount of glucagon released which delays gastric emptying and reducing appetite.

Weight loss

Semaglutide  and Tirzepatide  lower blood sugar and can reduce cardiovascular and stroke risks.

Improved A1C

Research shows an average loss of 15% body weight in patients studied.

Semaglutide and Tirzepatide are injected once a week with a very small needle subcutaneously. It may be injected into the skin on your stomach, thigh, or back of upper arm. Injection sites should be rotated each week. Your provider will provide education on how to inject prior to starting therapy during one of your visits. 

Most common side effects are: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, upset stomach, dizziness, feeling bloated, belching, gas, and heartburn. Many of these symptoms decrease or resolve over time as your body acclimates to the medication.

Most side affects are manageable by slow dosing and specific titration schedule ordered by your provider. 

Note some people do not experience side effects at all.

The current failure rate of people stopping or quitting medication due to side effects is approximately 3%. 

You SHOULD NOT use Semaglutide or Tirzepatide if you have a history of:

Diabetes Type 1

A personal or family history of medullary thyroid cancer

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Diabetic ketoacidosis

Pancreatitis

Stomach or intestinal d/o

Kidney disease

Eye problems caused by diabetes (retinopathy)

Pregnant or plan to get pregnant

Breastfeeding or plan to Breastfeed

Allergy to Semaglutide

Semaglutide and Tirzepatide are not covered by most Medicaid, Medicare and commercial plans. Prices range from $900 to $1300 per month for brand medications and are listed as in shortage.